Study examines the clinical characteristics and trends of post-COVID-19 condition (PCC) in U.S. veterans, showing the protective effect of vaccination and the need for precise symptom documentation for effective research and clinical care.
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN – Biotech Investments
EQS-News: PAION AG / Key word(s): Regulatory Admission PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN 28.09.2023 /